About the Organizers
New York, USA
Miriam Merad, MD, PhD
Miriam Merad, MD, PhD, is a Professor of Oncological Sciences and of Medicine (Hem/Onc division) at the Icahn School of Medicine at Mount Sinai in New York. Dr. Merad’s laboratory studies the mechanisms that regulate the development and function of innate myeloid cells including dendritic cells and macrophages. One of the major goals of her laboratory is to identify the contribution of these cells to the development and progression of tumor cells. Dr. Merad’s hypothesis suggests that tumors do not consist of a homogenous mass of genetically altered cells but rather include a large amount of innate myeloid cells that significantly contribute to tumor development. Dr. Merad established that tumor infiltrating dendritic cells could be targeted in vivo to promote the induction of tumor specific immunity. Currently, she is examining the contribution of tumor infiltrating macrophages to tumor progression and response to conventional and targeted therapies. She has authored more than 100 primary papers and review articles in high profile journals and obtained extensive NIH funding for her studies on dendritic cells and macrophage biology in mice and humans.
Hélène Salmon, PhD
Hélène Salmon is Assistant Professor of Oncological Sciences and the head of a junior group established at Icahn School of Medicine at Mount Sinai, New York. She will be moving to the Institut Curie, Paris, in April 2019. Her work identified the unique ability of the CD103+ dendritic cells (DCs) in transporting intact tumor antigen to the tumor draining lymph node, and established that these DCs are required for response to checkpoint blockade. Dr Salmon's prior work also shed light on the importance of the extracellular matrix in the control of T cell migration in human lung tumors. Her group aims to decipher the crosstalk between stromal cells, especially fibroblasts, and immune cells in peripheral tissues, with a strong focus on cancer lesions.
Amir Horowitz, PhD
Amir Horowitz, PhD is an Assistant Professor of Oncological Sciences and a member of the Precision Immunology Institute and the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. Dr. Horowitz’s work has contributed to developing an understanding of adaptive NK cells and their roles in microbial infections, cancers and following vaccination and transplantation. He pioneered the first studies of human NK cells by mass cytometry (CyTOFTM) and demonstrated an enormous breadth of phenotypic diversity and functions associated with specific HLA class I and KIR backgrounds. This research has led to the identification and characterization of numerous NK cell subset populations with unique activity and immunotherapeutic potential. This work and related future research will address his long-term career goal of understanding how immunogenetic variation governs the education of NK cells and their ability to function within dynamic environments.
François Lemoine, MD, PhD
François Lemoine, MD, PhD, is a Professor of Immunology at CIMI center in Paris and as the Director of the teaching department of Immunology, Faculty of Medicine - Sorbonne University, and national coordinator of the inter-universitary diploma (DIU) "Immunology and Biotherapies". His team is working on Head and Neck Squamous Cell Carcinoma, especially in the development of innovative biotherapies including cancer vaccines and combinational therapies.
São Paulo, Brazil
Roger Chammas, MD, PhD
Roger Chammas, MD, PhD concluded his studies in Medicine and got his PhD degree in Biochemistry at Universidade de São Paulo. Dr. Chammas is currently a Professor of Oncology at Faculdade de Medicina da Universidade de São Paulo. He also serves as chair for the Center for Translational Research in Oncology, a research unit for both basic and translational cancer research at Instituto do Câncer do Estado de São Paulo, a specialized institute for cancer management and oncology teaching and research associated with Universidade de São Paulo. His major interests are in the area of cancer biology (biochemistry and cancer cell biology), focusing in tumor progression, carbohydrate-dependent tumor markers and tumor microenvironment, as targets for combination therapy and molecular diagnostics through imaging in cancers.